Skip to main content
. 2015 Jan 31;14(4):917–932. doi: 10.1074/mcp.M114.045914

Fig. 3.

Fig. 3.

Strategy used to select malignancy-related PE biomarker candidates. Thirty proteins with higher levels in nonsmall cell lung cancer malignant pleural effusions (NSCLC-MPE) compared with benign diseases (tuberculosis [TB] and pneumonia [PN]) were identified and further selected by comparative analysis of nonsmall cell lung cancer malignant (NSCLC-MPE) and nonsmall cell lung cancer paramalignant pleural effusion (NSCLC-PMPE) proteome data sets, integration with NSCLC tissue transcriptome data sets, functional classification, consideration of novelty, and availability of commercial antibodies/ELISA kits.